IL138319A0 - MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) - Google Patents

MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)

Info

Publication number
IL138319A0
IL138319A0 IL13831999A IL13831999A IL138319A0 IL 138319 A0 IL138319 A0 IL 138319A0 IL 13831999 A IL13831999 A IL 13831999A IL 13831999 A IL13831999 A IL 13831999A IL 138319 A0 IL138319 A0 IL 138319A0
Authority
IL
Israel
Prior art keywords
diseases
compounds
ptpases
protein tyrosine
shp
Prior art date
Application number
IL13831999A
Other languages
English (en)
Original Assignee
Novo Nordisk As
Ontogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As, Ontogen Corp filed Critical Novo Nordisk As
Priority claimed from PCT/DK1999/000121 external-priority patent/WO1999046267A1/en
Publication of IL138319A0 publication Critical patent/IL138319A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/66Nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/18Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Electrodes Of Semiconductors (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Bipolar Transistors (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Control Of El Displays (AREA)
  • Indole Compounds (AREA)
IL13831999A 1998-03-12 1999-03-11 MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) IL138319A0 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DK34498 1998-03-12
DK48098 1998-04-03
DKPA199800938 1998-07-15
DKPA199801385 1998-10-28
DKPA199801612 1998-12-07
PCT/DK1999/000121 WO1999046267A1 (en) 1998-03-12 1999-03-11 Modulators of protein tyrosine phosphatases (ptpases)

Publications (1)

Publication Number Publication Date
IL138319A0 true IL138319A0 (en) 2001-10-31

Family

ID=27512769

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13831999A IL138319A0 (en) 1998-03-12 1999-03-11 MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)

Country Status (13)

Country Link
EP (1) EP1080095B1 (enExample)
JP (1) JP2002506072A (enExample)
KR (1) KR20010041814A (enExample)
CN (1) CN1300291A (enExample)
AT (1) ATE308546T1 (enExample)
AU (1) AU2713599A (enExample)
BR (1) BR9908726A (enExample)
CA (1) CA2323493A1 (enExample)
DE (1) DE69928100D1 (enExample)
HU (1) HUP0104984A3 (enExample)
IL (1) IL138319A0 (enExample)
NO (1) NO20004527L (enExample)
PL (1) PL342816A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA82827C2 (en) 2000-12-18 2008-05-26 Inhibitors against the production and release of inflammatory cytokines
CA2487891A1 (en) * 2002-06-05 2003-12-18 Institute Of Medicinal Molecular Design, Inc. Inhibitors against the activation of ap-1 and nfat
TWI280876B (en) * 2002-06-05 2007-05-11 Inst Med Molecular Design Inc Therapeutic drug for diabetes
CN1658872B (zh) 2002-06-06 2010-09-22 株式会社医药分子设计研究所 抗过敏药
KR20110028554A (ko) 2002-06-06 2011-03-18 가부시키가이샤 이야쿠 분지 셋케이 겐쿠쇼 O-치환 히드록시아릴 유도체
KR20070037578A (ko) * 2004-05-28 2007-04-05 알타나 파마 아게 테트라히드로피리도티오펜
ATE397000T1 (de) * 2004-06-04 2008-06-15 Nycomed Gmbh Tetrahydropyridothiophenen zur verwendung in der behandlung von krebs
JP2008501768A (ja) * 2004-06-11 2008-01-24 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規の化合物及びテトラヒドロピリドチオフェンの使用
PT1773816E (pt) * 2004-06-24 2015-04-29 Vertex Pharma Moduladores de transportadores de cassete de ligação de atp
EP1851229A1 (en) * 2005-02-09 2007-11-07 Nycomed GmbH Tetrahydropyridothiophenes for the treatment of proliferative diseases such as cancer
JP2008530053A (ja) * 2005-02-11 2008-08-07 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌の治療のための抗増殖性剤としてのテトラヒドロピリドチオフェン
AU2006290802B2 (en) * 2005-09-15 2012-06-07 F. Hoffmann-La Roche Ag 4-amino-thieno[3,2-c]pyridine-7-carboxylic acid derivatives
CN1939922B (zh) * 2005-09-27 2010-10-13 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的5H-噻吩[3,4-c]吡咯-4,6-二酮衍生物
SG10201401661RA (en) * 2009-12-04 2014-07-30 Sunovion Pharmaceuticals Inc Multicycle compounds and pharmaceutical compositions useful for the treatment of neurological disorders
CN102382076B (zh) * 2010-09-03 2016-08-17 中国医学科学院药物研究所 芳酮和芳酰胺类化合物及其制法和药物用途
CN102838625B (zh) * 2011-06-22 2015-04-15 中国科学院上海药物研究所 四氢吡啶并噻唑类化合物、其制备方法、包含该化合物的药物组合物及其用途
EP2948147B1 (en) * 2013-01-28 2019-03-13 H. Lundbeck A/S N-substituted-5-substituted phthalamic acids as sortilin inhibitors
CN104788425A (zh) * 2015-03-12 2015-07-22 佛山市赛维斯医药科技有限公司 一类含烟酸酰胺和哌啶结构ptp1b抑制剂、制备方法及其用途
CN106748999A (zh) * 2015-03-12 2017-05-31 佛山市赛维斯医药科技有限公司 一类含烟酸酰胺结构的ptp1b抑制剂、制备方法及其用途
CN104788424A (zh) * 2015-03-12 2015-07-22 佛山市赛维斯医药科技有限公司 含烟酸酰胺和哌啶结构的ptp1b抑制剂、制备方法及其用途
CN106866523A (zh) * 2015-03-12 2017-06-20 佛山市赛维斯医药科技有限公司 含烟酸酰胺结构的ptp1b抑制剂、制备方法及其用途
CN104829629B (zh) * 2015-03-26 2017-03-15 天津药物研究院有限公司 含磺酰胺基的四氢噻吩并[2,3‑c]吡啶衍生物、其制备方法和用途
CA3032302A1 (en) 2016-07-29 2018-02-01 Taleen G. Hanania Compounds and compositions and uses thereof
CN110087687A (zh) 2016-07-29 2019-08-02 赛诺维信制药公司 化合物、组合物及其用途
JP7146782B2 (ja) 2017-02-16 2022-10-04 サノビオン ファーマシューティカルズ インク 統合失調症を処置する方法
CN111183138A (zh) 2017-08-02 2020-05-19 赛诺维信制药公司 异色满化合物以及用途
KR102746817B1 (ko) 2018-02-16 2024-12-24 스미토모 파마 아메리카, 인크. 염, 결정 형태 및 이들의 제조 방법
MX2021010880A (es) 2019-03-14 2022-01-18 Sunovion Pharmaceuticals Inc Sales de un compuesto de isocromanilo y formas cristalinas, procesos de preparacion, usos terapeuticos y composiciones farmaceuticas de las mismas.
US12410191B2 (en) 2019-05-21 2025-09-09 Zhejiang Hisun Pharmaceutical Co., Ltd. Macrolide derivatives, preparation method and application thereof
AU2021257786A1 (en) 2020-04-14 2022-11-03 Sunovion Pharmaceuticals Inc. (S)-(4,5-dihydro-7H-thieno[2,3-c]pyran-7-yl)-N-methylmethanamine for treating neurological and psychiatric disorders
WO2021211191A1 (en) * 2020-04-14 2021-10-21 Purdue Research Foundation Novel lymphoid-specific tyrosine phosphatase (lyp) inhibitors

Also Published As

Publication number Publication date
EP1080095A1 (en) 2001-03-07
HUP0104984A2 (hu) 2002-04-29
EP1080095B1 (en) 2005-11-02
KR20010041814A (ko) 2001-05-25
AU2713599A (en) 1999-09-27
HUP0104984A3 (en) 2003-07-28
ATE308546T1 (de) 2005-11-15
CA2323493A1 (en) 1999-09-16
NO20004527D0 (no) 2000-09-11
DE69928100D1 (de) 2005-12-08
PL342816A1 (en) 2001-07-02
NO20004527L (no) 2000-11-07
JP2002506072A (ja) 2002-02-26
BR9908726A (pt) 2000-11-21
CN1300291A (zh) 2001-06-20

Similar Documents

Publication Publication Date Title
IL138319A0 (en) MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
BR0112453A (pt) Métodos de tratamento de doença metabólica do osso, psorìase, leucemia, câncer do cólon, do seio ou da próstata e de aumento da força de um osso e uso de compasso
MXPA03006771A (es) Anticuerpos modificados y metodos de uso.
SI1054887T1 (sl) Biciklicni pridinski in primidinski derivati kot receptorski antagonisti nevropeptida y
WO2000032555A8 (en) Derivatives of (+)-venlafaxine and methods of preparing and using the same
BR9911786A (pt) Inibidores heterocìclicos de p38
ATE415164T1 (de) (20s)-1alpha-hydroxy-2alpha-methyl und 2beta- methyl-19-nor vitamin d3 und ihre verwendung
EP1878725A3 (en) Pyrimidine derivatives and their use as CB2 modulators
MXPA04005444A (es) Ureas de 2-aminobenzotiazoles como moduladores de adenosina.
HUP0003351A2 (hu) 2-Szubsztituált-4,5-diaril-imidazolok, eljárás e vegyületek előállítására, e vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk
NO20014816D0 (no) Derivater av venlafaxin og fremgangsmåter for fremstilling og andvendelse av samme
DE60216952D1 (de) Beta-carbolin-derivate als ptp-inhibitoren
AU1520195A (en) Use of anti-tnf antibodies as drugs in treating diseases involving elevated interleukin-6 serum levels
PT1157042E (pt) Produção de anticorpos tetravalentes
DK1503778T3 (da) Formulering af en blanding af flavonoider og flavaner med fri B-ring som terapeutisk middel
MXPA05013711A (es) Derivados 3-sustituidos de 5,6-diaril-pirazin-2-carboxi-amida y -2-sulfonamida, como moduladores de cb1.
YU73004A (sh) Biciklične amino kiseline kao farmaceutska sredstva
PT1414809E (pt) Derivados de ácido indano-acético, sua utilização como agentes farmacêuticos e intermediários e método para a sua preparação
BR0213540A (pt) Compostos, método para o tratamento de enfermidades ou distúrbios em um paciente e composição farmacêutica que compreende os mesmos
EP1251126A3 (en) Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
BR0306738A (pt) Processo e aparelho para preparar partìculas cristalinas de uma substância, população de partìculas, e, composição farmacêutica
EP0797999A3 (en) Formulations of obesity protein
WO2004055201A3 (en) Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease
DE69520430D1 (de) Meta substituierte arylalkylamine und therapeutische und diagnostische verwendung davon
AU2003260436A1 (en) Pyrimidine compounds